tecovirimat + calcium acetate

**Tecovirimat + calcium acetate** is not a marketed fixed combination drug, but refers to the co-administration of two separate agents: tecovirimat, a small molecule antiviral approved for treatment of smallpox and active against orthopoxviruses, and calcium acetate, an oral phosphate binder primarily used in patients with end-stage renal failure to reduce serum phosphate. Tecovirimat acts by inhibiting the orthopoxvirus VP37 protein, blocking viral egress and spread[2][3][4]. Calcium acetate works by binding dietary phosphate in the gastrointestinal tract and preventing its absorption. Co-administration increases tecovirimat exposure by approximately 16% without requiring dose adjustment, but warrants monitoring for signs of tecovirimat-related adverse effects[1][2].

Brand names

TPOXX (for tecovirimat)PhosLo (for calcium acetate)

Other names

SIGA-246SIGA246SIGA 246ST-246ST246ST 246calcium ethanoate